Intuitive Surgical is a prominent medical technology company specializing in minimally invasive surgical systems, most notably the da Vinci Surgical System, and also offers the Ion endoluminal system for diagnostic procedures. Operating within the Healthcare sector's Medical Instruments & Supplies industry, the company's business model encompasses not only its core products but also training, service, and digital tools, supported by a global direct sales force. In its most recent reported quarters, ISRG demonstrated a trend of accelerating revenue growth, with Q4 2025 revenue at $2.87 billion and Q3 2025 at $2.51 billion, compared to Q2 2025 at $2.44 billion and Q1 2025 at $2.25 billion. Earnings per share also showed an upward trajectory, with actual EPS of $2.53 in Q4 2025 and $2.40 in Q3 2025, following $2.19 in Q2 2025 and $1.81 in Q1 2025. The company has a consistent pattern of beating analyst estimates for EPS, having exceeded expectations in Q4 2025, Q3 2025, Q2 2025, and Q4 2024. Historically, ISRG has shown a strong year-over-year growth trajectory in both revenue and EPS, with notable beats against analyst expectations. For instance, Q4 2025 saw actual EPS of $2.53 against an estimate of $2.30, and Q4 2024 actual EPS of $2.21 against an estimate of $1.79, indicating a pattern of exceeding projections. Recent news highlights Intuitive Surgical's projection of 13-15% da Vinci procedure growth for 2026, signaling continued but moderating momentum, and its strategic integration of artificial intelligence into its da Vinci platform to enhance surgical precision and decision support. Investors should watch for commentary on AI adoption and its impact on future revenue growth and competitive positioning, as well as the company's ability to navigate potential headwinds from U.S. reimbursement changes and international capital constraints in the upcoming quarters.
